Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amneal PharmaceuticalsAMRX -0.67%56 EV-to-EBIT is 19.54 as of Jul. 24, 2026, which is 16% above its 10-year median of 16.87. GuruFocus rates AMRX with a GF Score™ of 56/100 and a GF Value™ of $7.59 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 690 Drug Manufacturers companies, Amneal Pharmaceuticals ranks worse than 58.84% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Amneal Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was $6,463 Mil.
Amneal Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $419 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's EV-to-EBIT falls into.
Amneal Pharmaceuticals's current Enterprise Value is $8,195 Mil.
Amneal Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $419 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amneal Pharmaceuticals (AMRX) has a EV-to-EBIT of 19.54 as of Jul. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Amneal Pharmaceuticals and its competitors. This is 16% above median its historical median of 16.87. According to the industry distribution chart, Amneal Pharmaceuticals ranks #406 out of 690 companies in the Drug Manufacturers industry, placing it in the top 58.8%.
Is Amneal Pharmaceuticals' EV-to-EBIT too high?
Amneal Pharmaceuticals' current EV-to-EBIT of 19.54 is 16% above median its 10-year median of 16.87. The Drug Manufacturers industry median EV-to-EBIT is 15.46. Amneal Pharmaceuticals' value of 19.54 is 26.4% above this industry median. Based on the distribution chart, Amneal Pharmaceuticals ranks #406 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amneal Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' EV-to-EBIT compare to INDV and KNSA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #406 out of 690 companies for EV-to-EBIT. This places Amneal Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 15.46. Amneal Pharmaceuticals' value of 19.54 is 26.4% above this benchmark. While the company's 10-year median is 16.87 vs. the industry median of 15.46, Amneal Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.46, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amneal Pharmaceuticals's current EV-to-EBIT of 19.54 is 26.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Amneal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amneal Pharmaceuticals's current EV-to-EBIT is 19.54, which is 16% above median its own 10-year median of 16.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.59, compared to a current price of $17.84 — trading 135% above its estimated fair value. The current EV-to-EBIT is 19.54, which is 16% above median its 10-year median of 16.87 and 26.4% above the Drug Manufacturers industry median of 15.46. Amneal Pharmaceuticals' overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current EV-to-EBIT is 19.54 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?
Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued.
The current stock price of $17.84 is trading 135% above its estimated GF Value™ of $7.59.
GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for AMRX:
EV-to-EBIT: 19.54 (16% above median its 10-year median of 16.87)
GF Value™: $7.59 vs. price of $17.84 (135% above fair value)
Industry Position: 26.4% above the Drug Manufacturers median (#406 of 690)
No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
56GF Score
Get the complete analysis for AMRX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMRX has been successfully added to your 
